NCT02907567

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Cognition Therapeutics · Industry
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for 28 days. This trial may include up to 8 qualified investigator sites in Australia.

Detailed description

Screening procedures will occur up to 42 days. Eligible subjects will randomized at the clinic on Day 1 and receive the first dose of study drug. Dosing for 28 days thereafter off-site and a total of 5 clinic visits over the treatment period for safety and lab assessments. Then a 7 day post-treatment completion follow-up visit (Day 35) and End of Study for last safety assessments (Day 49).

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	CT1812	Active study drug
DRUG	Placebo	non-active study drug

Timeline

• Start date: 2016-09-01
• Primary completion: 2017-08-24
• Completion: 2017-09-01
• First posted: 2016-09-20
• Last updated: 2018-07-26

Locations

4 sites across 1 country: Australia